Irish data analytics and diagnostic commercialisation company Diaceutics said revenue continued to grow across its business over 2023 as demand for its services remained strong despite a challenging year for the industry as a whole.
In a trading update to the end of last year, Diaceutics said revenue was up 22 per cent to £23.7 million, with an order book that grew 57 per cent to £26.6 million.
Diaceutics, which provides data, analytics and technology-enabled services to the precision medicine market, said more than half its revenue is now recurring.
The year also saw Diaceutics secured four enterprise-wide engagements, with a combined value of $20.1 million.
Don’t leave PRSI benefits on the table - they can save you thousands of euro
For Avant Money CEO Niall Corbett it’s all about balance - ‘We have to lend money to make money.’
Striving for net zero will cost less than we thought, but it will not be plain sailing
LA fires lay bare the spectre of an uninsurable future
“We are pleased to report a strong performance across our business in 2023, against the backdrop of a challenging year for the pharmaceutical industry,” said Ryan Keeling, Diaceutics’ chief executive.
“To continue our growth trajectory despite this demonstrates the significant value our customers place on our differentiated offering, as reflected by the increasing number of precision medicines we are working with and enterprise-wide engagements secured to date. Our solid recurring revenue and order book growth in 2023, alongside our expanding product set, provides us with good momentum as we enter 2024.”
- Sign up for Business push alerts and have the best news, analysis and comment delivered directly to your phone
- Find The Irish Times on WhatsApp and stay up to date
- Our Inside Business podcast is published weekly – Find the latest episode here
